JP2020510050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510050A5 JP2020510050A5 JP2019549569A JP2019549569A JP2020510050A5 JP 2020510050 A5 JP2020510050 A5 JP 2020510050A5 JP 2019549569 A JP2019549569 A JP 2019549569A JP 2019549569 A JP2019549569 A JP 2019549569A JP 2020510050 A5 JP2020510050 A5 JP 2020510050A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- cell lymphoma
- composition according
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 244000309459 oncolytic virus Species 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 241000700584 Simplexvirus Species 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000005746 immune checkpoint blockade Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023066170A JP7654708B2 (ja) | 2017-03-15 | 2023-04-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
| JP2025043270A JP7869895B2 (ja) | 2017-03-15 | 2025-03-18 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471875P | 2017-03-15 | 2017-03-15 | |
| US62/471,875 | 2017-03-15 | ||
| PCT/US2018/022442 WO2018170133A1 (en) | 2017-03-15 | 2018-03-14 | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023066170A Division JP7654708B2 (ja) | 2017-03-15 | 2023-04-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020510050A JP2020510050A (ja) | 2020-04-02 |
| JP2020510050A5 true JP2020510050A5 (cg-RX-API-DMAC10.html) | 2021-04-22 |
Family
ID=61913527
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549569A Pending JP2020510050A (ja) | 2017-03-15 | 2018-03-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
| JP2023066170A Active JP7654708B2 (ja) | 2017-03-15 | 2023-04-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
| JP2025043270A Active JP7869895B2 (ja) | 2017-03-15 | 2025-03-18 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023066170A Active JP7654708B2 (ja) | 2017-03-15 | 2023-04-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
| JP2025043270A Active JP7869895B2 (ja) | 2017-03-15 | 2025-03-18 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200009204A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3595690A1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2020510050A (cg-RX-API-DMAC10.html) |
| CN (1) | CN110461346A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2018235944B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3056392A1 (cg-RX-API-DMAC10.html) |
| MA (1) | MA51630A (cg-RX-API-DMAC10.html) |
| MX (3) | MX2019010797A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018170133A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201590451A1 (ru) * | 2012-08-30 | 2016-05-31 | Эмджен Инк. | Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки |
| CA3071599A1 (en) * | 2017-08-07 | 2019-02-14 | Amgen Inc. | Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus |
| CN116870165A (zh) * | 2018-08-17 | 2023-10-13 | 北京奥源和力生物技术有限公司 | 用于治疗癌症的组合及其治疗用途 |
| CN116802278A (zh) * | 2020-09-18 | 2023-09-22 | 成都美杰赛尔生物科技有限公司 | 溶瘤病毒与经改造的免疫细胞联合治疗肿瘤 |
| US20240299540A1 (en) | 2021-02-05 | 2024-09-12 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| JP7697147B2 (ja) | 2021-06-03 | 2025-06-23 | 上▲海▼允英生物医▲薬▼科技有限公司 | 腫瘍溶解性ウイルスベクターおよびその適用 |
| TW202321458A (zh) * | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
| CN117653676A (zh) * | 2022-08-22 | 2024-03-08 | 上海长征医院 | 溶瘤病毒vg161与免疫检查点抑制剂在制备治疗骨与软组织肿瘤药物中的应用 |
| US12129634B2 (en) * | 2022-08-23 | 2024-10-29 | Vetta, Llc | Sink system |
| CN115463161A (zh) * | 2022-09-15 | 2022-12-13 | 广东天普生化医药股份有限公司 | 一种溶瘤病毒在制备治疗骨肉瘤的药物组合物中的应用 |
| CN116271052B (zh) * | 2022-11-11 | 2025-07-04 | 上海市普陀区中心医院 | 溶瘤病毒vg161或与免疫检查点抑制剂联用在治疗胃癌中的应用 |
| CN121335710A (zh) * | 2023-04-07 | 2026-01-13 | 上海复诺健生物科技有限公司 | 重组溶瘤病毒与检查点抑制剂的组合用于治疗癌症 |
| CN120648657A (zh) * | 2024-03-08 | 2025-09-16 | 上海锦斯生物技术有限公司 | 一种修饰的溶瘤病毒及其组合物 |
| CN119524123A (zh) * | 2024-11-08 | 2025-02-28 | 北京肿瘤医院(北京大学肿瘤医院) | 溶瘤病毒联合pd-1单抗在制备黑色素瘤治疗药物中的应用 |
| CN119792537B (zh) * | 2025-01-22 | 2025-10-21 | 常州大学 | 利巴韦林与pd-1抑制剂联合用药物组合物及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| JP2003535565A (ja) | 1998-12-31 | 2003-12-02 | アーチ ディベロプメント コーポレイション | 新生物疾患の治療に有用な組換え単純ヘルペスウイルス |
| AU2905199A (en) | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP4810042B2 (ja) | 2000-01-21 | 2011-11-09 | バイオヴェックス リミテッド | ヘルペスウイルス株 |
| CN1286303A (zh) | 2000-08-17 | 2001-03-07 | 上海市农业科学院生物技术研究中心 | 抗人龋齿致病菌蛋白基因及其制备方法 |
| EP1381280B1 (en) | 2001-03-27 | 2011-05-11 | Catherex, Inc. | Viral vectors and their use in therapeutic methods |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CN101230335B (zh) | 2007-01-22 | 2010-08-11 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
| CN101230334B (zh) | 2007-01-22 | 2011-06-01 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| ES2704632T3 (es) | 2011-09-08 | 2019-03-19 | Univ New York | Virus de herpes simplex oncolítico y sus usos terapéuticos |
| EA201590451A1 (ru) * | 2012-08-30 | 2016-05-31 | Эмджен Инк. | Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| ES2833425T3 (es) * | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| EP3217993A1 (en) * | 2015-07-20 | 2017-09-20 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
| US20190022203A1 (en) * | 2016-01-11 | 2019-01-24 | Turnstone Limited Partnership | Oncolytic virus and checkpoint inhibitor combination therapy |
| US11497781B2 (en) * | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
| EP3225253A1 (en) * | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
| JP2020501589A (ja) * | 2016-12-23 | 2020-01-23 | ウイルツ・バイオロジクス・リミテッド | がんの治療 |
-
2018
- 2018-03-14 WO PCT/US2018/022442 patent/WO2018170133A1/en not_active Ceased
- 2018-03-14 CN CN201880017970.9A patent/CN110461346A/zh active Pending
- 2018-03-14 CA CA3056392A patent/CA3056392A1/en active Pending
- 2018-03-14 EP EP18716700.2A patent/EP3595690A1/en active Pending
- 2018-03-14 AU AU2018235944A patent/AU2018235944B2/en active Active
- 2018-03-14 JP JP2019549569A patent/JP2020510050A/ja active Pending
- 2018-03-14 MX MX2019010797A patent/MX2019010797A/es unknown
- 2018-03-14 MA MA051630A patent/MA51630A/fr unknown
- 2018-03-14 US US16/493,376 patent/US20200009204A1/en not_active Abandoned
-
2019
- 2019-09-11 MX MX2024006614A patent/MX2024006614A/es unknown
- 2019-09-11 MX MX2025001102A patent/MX2025001102A/es unknown
-
2023
- 2023-04-14 JP JP2023066170A patent/JP7654708B2/ja active Active
-
2024
- 2024-04-02 AU AU2024202086A patent/AU2024202086A1/en not_active Abandoned
-
2025
- 2025-03-18 JP JP2025043270A patent/JP7869895B2/ja active Active
- 2025-07-31 US US19/287,666 patent/US20260102446A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| Adamson et al. | Novel approaches to inhibiting HIV-1 replication | |
| HRP20192337T1 (hr) | Makrociklični inhibitori pd-1/pd-l1 i cd80(b7-1)/pd-l1 protein/protein interakcija | |
| IL278423B2 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| JP2018522858A5 (cg-RX-API-DMAC10.html) | ||
| RU2016148645A (ru) | Антитела к в7-н1 и к ctlа-4 для лечения немелкоклеточного рака легкого | |
| JP2019527706A5 (cg-RX-API-DMAC10.html) | ||
| FI3728254T3 (fi) | Bentsyyliaminosubstituoidut pyridopyrimidinonit ja johdannaiset SOS1-estäjinä | |
| CY1122005T1 (el) | Ανθρωπινα αντισωματα κατα toy pd-l1 | |
| RU2017117664A (ru) | Комбинация | |
| CA3018932C (en) | Pharmaceutical combinations for the treatment of cancer | |
| JP2018529656A5 (cg-RX-API-DMAC10.html) | ||
| JP2016536286A5 (cg-RX-API-DMAC10.html) | ||
| JP2019506427A5 (cg-RX-API-DMAC10.html) | ||
| MY197236A (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2018521135A5 (cg-RX-API-DMAC10.html) | ||
| JP2015534580A5 (cg-RX-API-DMAC10.html) | ||
| JO3636B1 (ar) | مشتقات 4'-نيوكليوسيد بها استبدال في شكل مثبطات ناتج انتساخ عكسي ل hiv | |
| JP2011157399A5 (cg-RX-API-DMAC10.html) | ||
| HRP20250902T1 (hr) | Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela | |
| JP2015536964A5 (cg-RX-API-DMAC10.html) | ||
| MXPA05008527A (es) | Uso de artemisinina para tratar tumores inducidos por virus oncogenicos y para tratar infecciones virales. | |
| JP2019532047A5 (cg-RX-API-DMAC10.html) | ||
| JP2017514800A5 (cg-RX-API-DMAC10.html) |